These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9696850)

  • 21. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.
    Patick AK; Mo H; Markowitz M; Appelt K; Wu B; Musick L; Kalish V; Kaldor S; Reich S; Ho D; Webber S
    Antimicrob Agents Chemother; 1996 Feb; 40(2):292-7. PubMed ID: 8834868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.
    Doyon L; Tremblay S; Bourgon L; Wardrop E; Cordingley MG
    Antiviral Res; 2005 Oct; 68(1):27-35. PubMed ID: 16122817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L; Vivot A; Charpentier C; Bénard A; Visseaux B; Damond F; Matheron S; Chene G; Brun-Vezinet F; Descamps D;
    AIDS; 2013 Jan; 27(1):69-80. PubMed ID: 23018441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.
    Gong YF; Robinson BS; Rose RE; Deminie C; Spicer TP; Stock D; Colonno RJ; Lin PF
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2319-26. PubMed ID: 10952574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.
    Kolli M; Stawiski E; Chappey C; Schiffer CA
    J Virol; 2009 Nov; 83(21):11027-42. PubMed ID: 19706699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).
    Schmit JC; Ruiz L; Clotet B; Raventos A; Tor J; Leonard J; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1996 Aug; 10(9):995-9. PubMed ID: 8853733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
    J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML; Potts KE; Tucker SP; Blystone L; Stiebel TR; Stallings WC; McDonald JJ; Pillay D; Richman DD; Bryant ML
    Antimicrob Agents Chemother; 1997 Mar; 41(3):515-22. PubMed ID: 9055985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
    Mammano F; Petit C; Clavel F
    J Virol; 1998 Sep; 72(9):7632-7. PubMed ID: 9696866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays.
    Robinson LH; Myers RE; Snowden BW; Tisdale M; Blair ED
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1149-56. PubMed ID: 10954890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.
    La Seta Catamancio S; De Pasquale MP; Citterio P; Kurtagic S; Galli M; Rusconi S
    J Clin Microbiol; 2001 Mar; 39(3):1124-9. PubMed ID: 11230439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
    Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
    J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
    el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
    J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
    Larrouy L; Charpentier C; Landman R; Capitant C; Chazallon C; Yeni P; Peytavin G; Damond F; Brun-Vezinet F; Descamps D;
    AIDS; 2011 Nov; 25(17):2143-8. PubMed ID: 21904187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.